Galway-based connected health start-up, FeelTect, has announced the commercial launch of its pioneering wound care device, Tight Alright, starting in Thun Hospital, Switzerland.
The commercial launch coincides with the successful close of a €1.5 million investment round involving Irrus Investments, the Western Development Commission (WDC), and a network of angel investors.
Founded in 2019, FeelTect is transforming compression therapy with Tight Alright the world’s first connected health technology for measuring and monitoring compression therapy in real time.
The innovation aims to improve clinical accuracy, enhance patient outcomes, and support remote care management for chronic wounds such as venous leg ulcers.
FeelTect’s commercial launch comes on the back of strong clinical data, as explained by Andrew Cameron, CEO and Co-Founder of FeelTect.
“Our recent clinical studies show a threefold acceleration in healing rates for venous leg ulcer patients — a breakthrough that has the potential to redefine standards of wound care.”
Darren Burke, CTO and Co-Founder, added, “This launch marks a major milestone for FeelTect and for wound care globally. After years of rigorous testing and clinical validation, Tight Alright is now ready to empower clinicians and patients with real-time insights that will transform the model of care.”
The newly secured funding will support commercial rollout, regulatory expansion, and team growth as FeelTect scales operations from its headquarters in Spiddal.
The investment also positions the company to expand within Switzerland and pursue new markets in Europe, the United States, and Australia, where it already holds CE mark, FDA registration, and TGA certification, respectively.
Dr. Thomas Zehnder, Chief Physician and Co-Director of the Wound Centre at Thun Hospital, commented, “Compression therapy is a critical element to the successful treatment of patients with venous leg ulcers and many other indications.”
“Digital tools like FeelTect’s Tight Alright can advance our ability to control the dosage and maintenance of this gold standard treatment”.
Andrew Cameron highlighted the importance of the funding to the company’s pathway, “This investment enables us to bring Tight Alright to market and to patients who need it most.”
CEO of the Western Development Commission, Allan Mulrooney, commented, “FeelTect embodies the innovation and ambition we aim to support in the West of Ireland. Their success demonstrates how regional start-ups can make a global impact with world-class technology.”
The investment builds on early-stage support from the Western Investment Fund, which was instrumental in helping FeelTect navigate the complex regulatory and technical pathways of medical device development.
As FeelTect prepares for full commercial rollout, the company remains committed to advancing connected health technologies that deliver measurable improvements in patient outcomes while reinforcing Ireland’s reputation as a global MedTech hub.
“We’re proud to be growing our team and scaling our operations right here in Spiddal,” added Burke. “The west of Ireland has everything we need to support our journey to becoming a global MedTech leader.”
